title: Treating transcriptional addiction in small cell lung cancer.
abstract: Small cell lung cancer (SCLC) is a devastating tumor type with great therapeutic need. In this issue of Cancer Cell, Christensen and colleagues identify THZ1, a CDK7 inhibitor, as a potential therapy for SCLC. Using cells and mouse models, the authors show exquisite sensitivity of SCLC to transcriptional inhibition.
authors.affiliation: Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Augert
authors.affiliation: Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: dmacpher@fhcrc.org.
authors.forename: David
authors.initials: D
authors.lastname: MacPherson
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D014157:Transcription Factors / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D014157:Transcription Factors